ReviewAdvances in experimental medicine and biology2025
Optimal GVHD Prophylaxis.
Review in Advances in experimental medicine and biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Immune monitoring for relapse of acute myeloid leukemia after allogeneic stem cell transplantation in clinical laboratories.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Graft-versus-host disease (GVHD) limits the curative potential of allogeneic hematopoietic cell transplant (HCT). This immune-mediated disease can result in multisystem organ morbidity, chronic debility, or mortality. Prevention of GVHD is a primary objective when treating patients with allogeneic HCT. While many factors are considered in transplant planning, the choice of GVHD prophylaxis is a critical and modifiable factor that impacts the risk of GVHD. Each regimen is associated with variable GVHD risk, immune reconstitution, infection risk, graft-versus-tumor effect, and drug-related adverse events. Furthermore, the utility of a specific regimen must be considered in the context of the transplant platform such as conditioning regimen and donor choice. In this chapter, we review the current state of GVHD prophylaxis, highlighting the historical standard approach of calcineurin inhibitor-based regimens, as well as the emerging standard of post-transplant cyclophosphamide.
Indexed as
Identifiers
40488825What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.